Starlight Therapeutics, a Subsidiary of Lantern Pharma, Welcomes Dr. Marc Chamberlain as Chief Medical Officer with Focus on CNS & Brain Cancers

Written By Kathleen Otto

Starlight Therapeutics, a subsidiary of Lantern Pharma, reinforces its commitment to advancing treatments for CNS and brain cancers with the appointment of Dr. Marc Chamberlain as Chief Medical Officer, overseeing strategic clinical operations and spearheading AI-enabled drug development initiatives.

Kathleen Otto
Previous

Nanoscope's MCO-010 Gene Therapy for Retinitis Pigmentosa Gets FDA Nod for BLA Approval
Next

NexPoint Launches $31M Life Sciences Investment Trust for Minnesota Property